Tirilazad
From Wikipedia, the free encyclopedia
Tirilazad
|
|
Systematic (IUPAC) name | |
(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one | |
Identifiers | |
CAS number | |
ATC code | N07 |
PubChem | |
Chemical data | |
Formula | C38H52N6O2 |
Mol. mass | 624.859 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Tirilazad is a drug proposed for use in the treatment of stroke, though results so far have been mixed.[1]
[edit] References
- ^ Tirilazad for acute ischaemic stroke. Retrieved on 2007-07-28.